炎症性腸疾患の組織修復の研究オルガノイド技術を利用する (ORGANOIDS)
Inflammatory Bowel Diseases (IBD) are chronic inflammations of the gastrointestinal tract. Regardless of the etiology, a common trait of IBD pathogenesis is the inflammatory damage inflicted on the intestinal mucosa and the loss of intestinal epithelial barrier integrity. Therefore, understanding the mechanisms that govern IEC's capacity to maintain barrier function and to orchestrate mucosal healing is considered a major goal in translational research. The investigators are interested in understanding how the inflammatory environment present in the intestinal mucosa, of IBD patients influences epithelial cells capacity to govern repair. The complexities of the cytokine and metabolic milieu present in IBD patients render the study of the contribution of each cytokine, metabolite, and intracellular pathway extremely complicated. Therefore, most of the processes that govern tissue regeneration are studied with the use of mouse models that recapitulate one or multiple features of IBD and allow for genetical modifications of the gene and pathway of interest. While mouse models are uniquely suited to study the complex crosstalk between the immune system, the microbiota, and the intestinal epithelia, they introduce the important problem of species-specific differences, which can hamper the translational value of mouse studies.
To overcome these shortcomings, the investigators propose to explore the influence of cytokines and metabolites in digestive organoids derived from patients and controls. Importantly, it was demonstrated that gene expression and innate immune responses are altered in primary organoids derived from patients with IBD, including altered ability to proliferate, respond to cytokines, metabolic capacity, and efficiently form organoids suggesting that major differences between patient's and control's epithelial cell biology can be faithfully replicated in this system.
Given these premises, the investigators propose the following objectives:
Primary objective:
The main objective of this study is to establish that patient's epithelial cells from inflamed mucosae have decreased ability to repair the intestinal mucosa, as compared to epithelial cells from non-inflamed regions in the same patient, or to control subject with no inflammatory digestive diseases.
The investigators will explore this question both deriving organoids from clinical samples and exposing them to pro inflammatory cytokines and metabolites in vitro, as well as by analyzing repair responses from the aforementioned clinical samples ex vivo.
Secondary objective
The secondary goals of this study are:
- To compare organoids derived from: epithelia in inflamed mucosa of IBD patients, epithelia in non-inflamed mucosa of IBD patients, and epithelia from the mucosa of non-IBD controls in their capacity to mount a repair response in response to inflammatory cytokines or luminal metabolites.
Namely the investigators will evaluate the following parameters:
- Their capacity to proliferate.
- Their ability to survive treatment with pro-inflammatory cytokines
- The activation of intracellular pathways associated with cell death.
- Their overall metabolic activity.
- The balance between stem and differentiated epithelial cell types.
- The transcriptional activation of protective pathways such as those associated with proliferation, migration, differentiation and cell survival.
- To evaluate hallmarks of tissue repair in biopsies derived from epithelia in inflamed mucosa of IBD patients, epithelia in non-inflamed mucosa of IBD patients, and epithelia from the mucosa of non-IBD controls, and to correlate them to the levels of inflammatory cytokines, luminal metabolites and overall disease severity. Namely the investigators will evaluate the following parameters:
- The abundance of proliferating cells.
- The activation of intracellular pathways associated with cell death and survival.
- Their overall metabolic activity.
- The balance between stem and differentiated epithelial cell types.
- The transcriptional activation of protective pathways such as those associated with proliferation, migration, differentiation and cell survival.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- 適用できない
連絡先と場所
研究連絡先
研究連絡先
- 名前:Lucas GUILLO
- 電話番号:+33 0491335817
- メール:promotion.interne@ap-hm.fr
研究場所
-
-
-
Marseille、フランス、13915
- 募集
- Nord Hospital
-
コンタクト:
- Lucas GUILLO
- 電話番号:+33 0491335817
- メール:promotion.interne@ap-hm.fr
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
For IBD group the inclusion criteria will be:
- Patients of either sex aged 18 years or older
- Patient that have read the information form and signed consent
- Patient covered with health insurance
- Patients with Crohn's Disease or ulcerative colitis in accordance with accepted clinical, endoscopic, histological and/or radiologic criteria, regardless of the level, severity of the disease or duration of disease progression.
- Patients with colonic involvement of Crohn's disease or ulcerative colitis
- Patients undergoing a screening colonoscopy in the context of IBD disease follow-up OR undergoing intestinal resection for IBD disease aggravation
For control group the inclusion criteria will be:
- Patients of either sex aged 18 years or older
- Patient that have read the information form and signed consent
- Patient covered with health insurance
- Patients undergoing a screening colonoscopy in the context of a family history of colonic neoplasia, follow-up of colonic polyps or functional intestinal disorders OR undergoing intestinal resection for intestinal neoplasia, occlusive syndrome or colostomy
The non-inclusion criteria for IBD group will be:
- Contraindication to the anaesthetic or colonoscopy procedure
- Patients without colonic involvement of Crohn's disease or ulcerative colitis
- Patients of Adults without legal capacity
- Patients in Health and Social Establishments
- Persons in emergency situations
- Persons deprived of their liberty
- Non-affiliated to a social security scheme
- Absence or refusal of the informed consent
The non-inclusion criteria for control group will be:
- IBD disease revealed during colonoscopy or gastrointestinal resection
- Patient suffering from Immune-Mediated Inflammatory Diseases (IMIDs)
- Contraindication to the anaesthetic or colonoscopy procedure
- Patients of Adults without legal capacity
- Patients in Health and Social Establishments
- Persons in emergency situations
- Persons deprived of their liberty
- Non-affiliated to a social security scheme
- Absence or refusal of the informed consent
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:基礎科学
- 割り当て:非ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
偽コンパレータ:Control group
Patients of either sex aged 18 years or older and undergoing a screening colonoscopy in the context of a family history of colonic neoplasia, follow-up of colonic polyps or functional intestinal disorders OR undergoing intestinal resection for intestinal neoplasia, occlusive syndrome or colostomy |
Collection of 10 colonic biopsies in healthy tissue Collection of a portion of healthy mucous membrane |
|
実験的:IBD group
Patients of either sex aged 18 years or older with Crohn's Disease or ulcerative colitis in accordance with accepted clinical, endoscopic, histological and/or radiologic criteria, regardless of the level, severity of the disease or duration of disease progression or patients undergoing a screening colonoscopy in the context of IBD disease follow-up OR undergoing intestinal resection for IBD disease aggravation |
Collection of a portion of healthy mucous membrane Collection of 10 colonic biopsies in IBD inflamed tissue Collection of a portion of IBD inflamed mucous membrane |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Repair status of IBD patient's epithelial cells from inflamed mucosae
時間枠:From enrollmet to the end of following at 1 month
|
To establish that patient's epithelial cells from inflamed mucosae have decreased ability to repair the intestinal mucosa, as compared to epithelial cells from non-inflamed regions in the same patient, or to control subject with no inflammatory digestive diseases |
From enrollmet to the end of following at 1 month
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Evaluate the molecular mechanism involved in the reduced capacity of epithelial cells of IBD patients to repair intestinal mucosa
時間枠:From enrollment to the end of following at 1 month
|
Evaluation of:
|
From enrollment to the end of following at 1 month
|
|
Genetically determine the involvement of cell death and protective pathways that reduce repair capacity in patients.
時間枠:From enrollment to the end of following at 1 month
|
After a genetically modify with CRISPR-CAS9 technology:
|
From enrollment to the end of following at 1 month
|
|
3. Explore the activation of molecular mechanisms identified in patient biopsies and correlate them with the inflammatory environment present in the patient's tissues
時間枠:From enrollment to the end of following at 1 month
|
|
From enrollment to the end of following at 1 month
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- RCAPHM24_0062
- 2024-A00510-47 (その他の識別子:EUdraCT)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。